References
- JoyMSMatzkeGRArmstrongDKMarxMAZarowitzBJA primer on continuous renal replacement therapy for critically ill patientsAnn Pharmacother19983233623759533067
- TrotmanRLWilliamsonJCShoemakerDMSalzerWLAntibiotic dosing in critically ill adult patients receiving continuous renal replacement therapyClin Infect Dis20054181159116616163635
- ProwleJRSchneiderABellomoRClinical review: Optimal dose of continuous renal replacement therapy in acute kidney injuryCrit Care201115220721489322
- BuggeJFPharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patientsActa Anaesthesiol Scand200145892993411576041
- González de MolinaFJFerrerRAppropriate antibiotic dosing in severe sepsis and acute renal failure: factors to considerCrit Care201115417521861865
- ChoiGGomersallCDTianQJoyntGMLiAMLipmanJPrinciples of antibacterial dosing in continuous renal replacement therapyBlood Purif201030319521220924175
- SeylerLCottonFTacconeFSRecommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyCrit Care2011153R13721649882
- ChurchwellMDMuellerBADrug dosing during continuous renal replacement therapySemin Dial200922218518819426426
- ThompsonAJDrug dosing during continuous renal replacement therapiesJ Pediatr Pharmacol Ther20081329911323055873
- MatzkeGRAronoffGRAtkinsonAJJrBennettWMDeckerBSEckardtKUDrug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney Int201180111122113721918498
- GlossopASeidelJDosing regimes for antimicrobials during continuous veno-venous haemofiltration (CVVH)J Intensive Care Soc200892160165
- GavazaPBrownCMLawsonKARascatiKLSteinhardtMWilsonJPPharmacist reporting of serious adverse drug events to the Food and Drug AdministrationJ Am Pharm Assoc (2003)2012525e109e11223023857
- NebekerJRBarachPSamoreMHClarifying adverse drug events: a clinician’s guide to terminology, documentation, and reportingAnn Intern Med20041401079580115148066
- NebekerJRHurdleJFHoffmanJRothBWeirCRSamoreMHDeveloping a taxonomy for research in adverse drug events: potholes and signpostsProc AMIA Symp200149349711825237
- ParkSKChunHJKimDWImTHHongHJYiHJAcute Physiology and Chronic Health Evaluation II and Simplified Acute Physiology Score II in predicting hospital mortality of neurosurgical intensive care unit patientsJ Korean Med Sci200924342042619543503
- SchetzMDrug dosing in continuous renal replacement therapy: general rulesCurr Opin Crit Care200713664565117975384
- RobertsDMRobertsJARobertsMSRENAL Replacement Therapy Study InvestigatorsVariability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic studyCrit Care Med20124051523152822511133
- MontazeriMCookDJImpact of a clinical pharmacist in a multidisciplinary intensive care unitCrit Care Med1994226104410488205814
- Kane-GillSLKirisciLVerricoMMRothschildJMAnalysis of risk factors for adverse drug events in critically ill patients*Crit Care Med201240382382822036859
- KucukarslanSNPetersMMlynarekMNafzigerDAPharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine unitsArch Intern Med2003163172014201814504113
- MergenhagenKABlumSSKuglerAPharmacist- versus physician-initiated admission medication reconciliation: impact on adverse drug eventsAm J Geriatr Pharmacother201210424225022819386
- KoppBJMrsanMErstadBLDubyJJCost implications of and potential adverse events prevented by interventions of a critical care pharmacistAm J Health Syst Pharm200764232483248718029956
- KlopotowskaJEKuiperRvan KanHJOn-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention studyCrit Care2010145R17420920322
- KaneSLWeberRJDastaJFThe impact of critical care pharmacists on enhancing patient outcomesIntensive Care Med200329569169812665997